DOCSLIB.ORG

Curriculum Vitae

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curriculum Vitae CURRICULUM VITAE Name : Prof. Devrim GOZUACIK, MD PhD Address : Koç University, School of Medicine, KUTTAM Research Center for Translational Medicine, Topkapi 34010, Istanbul, TURKEY. Phone : +90 212 467 87 00 E-mail : [email protected] Orcid ID : https://orcid.org/0000-0001-7739-2346 EDUCATION 2001, Ph.D. of Molecular Cell Biology, Paris Pasteur Institute and Paris-Sud (XI) University. 1997, M.Sc. (French D.E.A. degree) of Biochemistry, Ecole Polytechnique and Paris-Sud University. 1995, Medical doctor (MD) degree, Hacettepe University, Faculty of Medicine (in English). 1994, Research fellow, Dept. of Tumor Biology, Rotterdam Erasmus Medical Center. 1989-1995, Student researcher, Hacettepe Children’s Hospital Medical Biology Dept. and Hacettepe Oncology Institute. EMPLOYMENT June 2020-today, Professor, School of Medicine, KUTTAM Research Center for Translational Medicine, Koç University. 2018-today, Affiliate Member, Autophagy, Inflammation and Metabolism (AIM) Center of Biomedical Research Excellence, University of New Mexico Health Sciences Center, USA. 2018-today, Part-Time Senior Researcher, SUNUM Nanotechnology Research and Application Center. 2016-2020, Co-Founder and Board Member, EFSUN Nanodiagnostics Center of Excellence. 2018-2020, Professor, Molecular Biology Genetics and Bioengineering Program, Sabanci University. 2011-2018, Associate Professor, Molecular Biology Genetics and Bioengineering Program, Sabanci University. Sept. 2006-2011, Assistant Professor, Biological Sciences and Bioengineering Program, Sabanci University. 2001-2006, Postdoctoral fellow, Weizmann Institute of Science (Adi Kimchi Lab). CITATIONS AND H-INDEX 8338 citations in the Science Citation Index (SCI, Thomson-Reuters), h-index: 25. 8710 citations in Scopus, h-index: 25 13670 citations in Google Scholar, h-index: 28. 11 publications with >100 citations. 1 AWARDS 2015, Elginkan Foundation Technology Award (with the SUTAB medical device team). 2014, Turkish Press Association, Sedat Simavi Health Sciences Award. 2014, Istanbul Kultur University, Prof. Onder Oztunali Science Award. 2008, Turkish Academy of Sciences Outstanding Young Scientist Award (TUBA-GEBIP Award). 2006, European Molecular Biology Organization, EMBO, Strategical Development and Installation Award. 2006, Selected by Hoffmann-La Roche Pharmaceuticals among the “Leading Bioscientists of the Next Decade” 2004-2006, European Union "Marie Curie Actions" Postdoctoral Fellowship. 2002-2004, Weizmann Institute Feinberg Graduate School Postdoctoral Fellowship. 2001-2002, French Organisation For Medical Research (FRM) Postdoctoral Fellowship. 1999-2001, French Cancer Research Association (ARC) PhD Scholarship. 1996-1999, TUBITAK / NATO A1 PhD Full Scholarship. INTERNATIONAL AND NATIONAL PROFESSIONAL SERVICES A) International professional services, 2018-today, International Council Member, Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence, University of New Mexico Health Sciences Center, USA (www.autophagy.center). 2010-today, Board of Directors Member, International Cell Death Society (ICDS) (Based in New York) (www.celldeath-apoptosis.org). 2016-today, Associate Editor, Autophagy journal (Taylor & Francis Group. SCI Impact Factor 2017: 11.1) 2017-today, Editorial Board Member, Cell Communication and Signaling journal (Springer Nature Publishing. SCI Impact Factor 2017: 3.94) 2010-2016, Editorial Board Member, Autophagy journal (SCI Impact Factor 2010-16: 9.1-12) 2007-2019, Referee, Nature Communications, PNAS, Autophagy, Cell Death and Differentiation, Cancer Research, Oncogene, Oncotarget, Human Molecular Genetics, Scientific Reports, Cell Death and Disease, Cell Signaling, Endocrine-Related Cancer, Molecular Cancer, , BMC Cell Biology, Biochimica Biophysica Acta (BBA), FEBS Letters, Experimental Biology and Medicine, Current Cancer Drug Targets, Biotechniques, Functional & Integrative Genomics Journal, Journal of Oncology, Turkish Journal of Biology, Turkish Journal of Medical Sciences, Frontiers in Anti-Cancer Drug Discovery. 2007-today: Grant or academic referee/advisor, Cancer Research, UK (United Kingdom), Wellcome Trust (United Kingdom), The Health Research Board, (Ireland) ve Research Foundation Flanders, FWO (Belgium), KU Leuven, (Belgium), Goethe University (Germany), University of Pretoria (South Africa), University of Florida (USA). 2 B) National professional services, 2018-today, Part-Time Senior Researcher, SUNUM Nanotechnology Research and Application Center. 2016-2020, Co-founder and Board Member, EFSUN Nanodiagnostics Center of Excellence. 2016-2019, Scientific Advisory Board Member, TUSEB Biotechnology Institute 2009-2018, Contributing Faculty, SUNUM Nanotechnology Research and Application Center. 2016-2017, Founding Member and Board Member, Turkish Cell Death Research Society (HOAD). 2011-2013, Founding Member and Board Member, Turkish Molecular Biology Society (MBD). 2018, TUBITAK Science Awards Referee, TUBITAK (Turkish Research Agency). 2018, TUSEB Aziz Sancar Science Awards Referee, TUSEB Ministry of Health of the Republic of Turkey (Equivalent of the NIH in the US). (Website: www.tuseb.gov.tr/english). 2013-today, TUBA GEBIP Awards Referee (7x), TUBA Academic Referee (2x) and Scientific Book Translation Award Referee (2x), Turkish Academy of Sciences (TUBA). 2014-today, Editorial Board Member, Turkish Journal of Biology (TUBITAK Publishing. SCI Impact Factor 2017: 1.04) 2014, Guest Co-Editor, Turkish Journal of Biology 2013, Academic Advisor, Izmir High Technology Institute, Gebze Technical University, Erciyes University, Acibadem University. 2012- today, Grant Referee, TUBITAK (National Science and Technology Council of Turkey), TR Ministry of Development, Hacettepe University, Uludag University, Ankara University, Gebze Technical University, Dokuz Eylul University. C) Scientific Meeting Organization (As a primary organizer or co-organizer), 1) 1st International Cell Death Research Congress, 9 Eylul University, 4-7 May 2016, Izmir, Turkey. 2) 1st Autophagy Lab Techniques Practical Course, Sabanci University, 2 May 2016, Istanbul, Turkey. 3) 2nd Karakoy Autophagy Symposium, Karakoy Minerva Han, 3 May 2016, Istanbul, Turkey. 4) 1st Karakoy Autophagy Symposium, Karakoy Minerva Han, 22 October 2014, Istanbul, Turkey. 5) International Cell Death Society (ICDS) Conference on Multidisciplinary Approaches in Cell Death Research, 28-31 May 2010, Antalya, Turkey. 6) European Molecular Biology Organization (EMBO) International Forum, 20-22 February 2008, Bogazici University, Istanbul, Turkey. 7) International Cell Death Symposium, Cerrahpasa Medical Faculty, 9 April 2008, Istanbul, Turkey. 3 INVITED LECTURES A) Keynote/Plenary Invited talks and/or Chairperson (International Meetings) 1) International Cell Death Society (ICDS) Conference on: "Cell Death through the Ages: 25th Anniversary Meeting", 27-30 June, 2019, New York, USA. 2) Annual Meeting and Symposium of the Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence, 22 February, 2019, Albuquerque, New Mexico, USA. 3) Keystone Conference on Autophagy: From Model Systems to Therapeutic Opportunities, 17—21 February, 2019, Santa Fe, New Mexico, USA. 4) 4th INDERCOS Dermatology and Cosmetology Congress, 27-30 March 2019, Istanbul, Turkey. 5) European Federation For Pharmaceutical Sciences Annual Meeting, 24-26 May, 2018, Athens, Greece. 6) EMBO Young Scientist Forum, 5-6 January 2018, Istanbul, Turkey. 7) International Cell Death Society (ICDS) Conference on: "Cell Death in Development and Disease", June 18-20, 2017, Rehovot, Israel. 8) VI. International Congress of Molecular Medicine, 22-25 May 2017 Istanbul, Turkey. 9) 4rd General Assembly Meeting of HealthyMinorCereals, 11 – 12 May, 2017, Greece. 10) First Joint WGs Meeting of TRANSAUTOPHAGY (COST Action CA15138), 6-7 October 2016, Warsaw, Poland. 11) 41st FEBS Congress on "Molecular ans Systems Biology for a Better Life", 3-8 Spetember 2016, Ephesus, Turkey (Cancelled). 12) International Cell Death Society (ICDS) Conference on: "Cell Death and its Translational Ramification, 2-5 June, 2016, Cork, Ireland. 13) 3rd General Assembly Meeting of HealthyMinorCereals, 10-11 May 2016, Berlin, Germany. 14) 1st International Cell Death Research Congress, 04-07 May 2016, Izmir, Turkey. 15) 2nd Karakoy Autophagy Symposium and 1st Autophagy Practical Course, 3 May 2016, Istanbul, Turkey. 16) Black Forest Winter Conference on Autophagic Membrane Trafficking and Dynamics in Ageing and Disease, 29-31 January 2016, Freiburg, Germany. 17) 1st Pharmacogenomics Summit, 27-28 November 2015, Istanbul, Turkey. 18) International Cofactor Life Sciences Conference (ICLS), 21-22 November 2015, Istanbul, Turkey. 19) 1st Karakoy Autophagy Symposium, 22 October 2014, Istanbul, Turkey. 20) TUBITAK-USA Cancer and Cancer Stem Cells Workshop, 8-10 October 2015, Manisa, Turkey. 21) 3rd International BAU Drug Design Congress, 1-3 October 2015, Istanbul, Turkey. 22) 24th International Symposium on Morphological Sciences, 2-6 September 2015, Istanbul, Turkey. 23) EMBO (European Molecular Biology Organization)-Cancer YIP Sectoral Meeting 2-4 September 2015, Prague, Czech Republic. 4 24) International Cell Death Society (ICDS) Conference on: Implementation of Knowledge of Cell Death, 28-30 May 2015, Prague, Czech Republic. 25) 5th International Congress of Molecular Medicine: From Cell to Bedside, 20-22 May 2015, Izmir, Turkey. 26) The European Association for Cancer Research (EACR) Sponsored 3nd Anticancer Agents Development Congress,
Load more

Recommended publications
  • Neurotrophin-3 Production Promotes Human Neuroblastoma Cell Survival by Inhibiting Trkc-Induced Apoptosis
    Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis Jimena Bouzas-Rodriguez, … , Servane Tauszig-Delamasure, Patrick Mehlen J Clin Invest. 2010;120(3):850-858. https://doi.org/10.1172/JCI41013. Research Article Oncology Tropomyosin-related kinase receptor C (TrkC) is a neurotrophin receptor with tyrosine kinase activity that was expected to be oncogenic. However, it has several characteristics of a tumor suppressor: its expression in tumors has often been associated with good prognosis; and it was recently demonstrated to be a dependence receptor, transducing different positive signals in the presence of ligand but inducing apoptosis in the absence of ligand. Here we show that the TrkC ligand neurotrophin-3 (NT-3) is upregulated in a large fraction of aggressive human neuroblastomas (NBs) and that it blocks TrkC-induced apoptosis of human NB cell lines, consistent with the idea that TrkC is a dependence receptor. Functionally, both siRNA knockdown of NT-3 expression and incubation with a TrkC-specific blocking antibody triggered apoptosis in human NB cell lines. Importantly, disruption of the NT-3 autocrine loop in malignant human neuroblasts triggered in vitro NB cell death and inhibited tumor growth and metastasis in both a chick and a mouse xenograft model. Thus, we believe that our data suggest that NT-3/TrkC disruption is a putative alternative targeted therapeutic strategy for the treatment of NB. Find the latest version: https://jci.me/41013/pdf Research article Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis Jimena Bouzas-Rodriguez,1 Jorge Ruben Cabrera,1 Céline Delloye-Bourgeois,1 Gabriel Ichim,1 Jean-Guy Delcros,1 Marie-Anne Raquin,2 Raphaël Rousseau,3 Valérie Combaret,3 Jean Bénard,4 Servane Tauszig-Delamasure,1 and Patrick Mehlen1 1Apoptosis, Cancer and Development Laboratory–Equipe labellisée “La Ligue,” CNRS UMR5238, Université de Lyon, France.
    [Show full text]
  • Ephrinb3 Is an Anti-Apoptotic Ligand That Inhibits the Dependence Receptor Functions of Epha4 Receptors During Adult Neurogenesis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1793 (2009) 231–238 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbamcr EphrinB3 is an anti-apoptotic ligand that inhibits the dependence receptor functions of EphA4 receptors during adult neurogenesis Céline Furne a,1, Jerome Ricard b,1, Jorge Ruben Cabrera a, Laurent Pays a, John R. Bethea b, Patrick Mehlen a,⁎,2, Daniel J. Liebl b,⁎,2 a Laboratory Apoptosis Cancer and Development, CNRS UMR 5238, Center Léon Bérard, University of Lyon, Lyon, France b The Miami Project to Cure Paralysis and Department of Neurosurgery, University of Miami School of Medicine, Miami, FL, USA article info abstract Article history: Eph receptors have been implicated in regulating a diverse array of cellular functions in the developing Received 18 December 2007 nervous system. Recently, Eph receptors have been shown to promote cell death in adult germinal zones; Received in revised form 2 September 2008 however, their mechanisms of action remain ill-defined. In this study, we demonstrate that EphA4 is a new Accepted 15 September 2008 member of the dependence receptors family, which can initiate cell death in the absence of its ligand Available online 7 October 2008 ephrinB3. Upon removal of its ligand, EphA4 triggers cell death that is dependent on caspase activation as caspase inhibitors prevent cell death. EphA4 itself is cleaved by caspase-3-like caspase in the intracellular Keywords: Ephrin domain at position D773/774, which is necessary for cell death initiation as mutation of the cleavage site Eph receptor abolishes apoptosis.
    [Show full text]
  • View Open Access Neurodegeneration in Alzheimer's Disease: Caspases and Synaptic Element Interdependence Dale E Bredesen1,2
    Molecular Neurodegeneration BioMed Central Review Open Access Neurodegeneration in Alzheimer's disease: caspases and synaptic element interdependence Dale E Bredesen1,2 Address: 1Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA USA 94945 and 2Department of Neurology, University of California, San Francisco, CA USA 94143 Email: Dale E Bredesen - [email protected] Published: 26 June 2009 Received: 4 March 2009 Accepted: 26 June 2009 Molecular Neurodegeneration 2009, 4:27 doi:10.1186/1750-1326-4-27 This article is available from: http://www.molecularneurodegeneration.com/content/4/1/27 © 2009 Bredesen; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Extensive genetic, biochemical, and histological evidence has implicated the amyloid-β peptide (Aβ) in Alzheimer's disease pathogenesis, and several mechanisms have been suggested, such as metal binding, reactive oxygen species production, and membrane pore formation. However, recent evidence argues for an additional role for signaling mediated by the amyloid precursor protein, APP, in part via the caspase cleavage of APP at aspartate 664. Here we review the effects and implications of this cleavage event, and propose a model of Alzheimer's disease that focuses on the critical nature of this cleavage and its downstream effects. Review: programmed cell death, cell death revealed a more active, and more plastic, role for the cell signaling, and neurodegenerative disease in its own life/death decision than was previously appre- Many of the diseases that affect the nervous system feature ciated.
    [Show full text]
  • Control of Cell Death/Survival Balance by the MET Dependence Receptor
    RESEARCH ARTICLE Control of cell death/survival balance by the MET dependence receptor Leslie Duplaquet1, Catherine Leroy1†, Audrey Vinchent1†, Sonia Paget1, Jonathan Lefebvre1, Fabien Vanden Abeele2, Steve Lancel3, Florence Giffard4, Re´ jane Paumelle3, Gabriel Bidaux5, Laurent Heliot5, Laurent Poulain4, Alessandro Furlan1,5*, David Tulasne1* 1Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T - Mechanisms of Tumorigenesis and Targeted Therapies, Lille, France; 2Univ. Lille, Inserm, U1003 - PHYCEL - Physiologie Cellulaire, Lille, France; 3Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, Lille, France; 4Normandie Universite´, UNICAEN, INSERM U1086 ANTICIPE, UNICANCER, Cancer Centre F. Baclesse, Caen, France; 5Univ. Lille, CNRS, UMR8523 - PhLAM – laboratoire de Physique des Lasers, Atomes et Mole´cules, Lille, France Abstract Control of cell death/survival balance is an important feature to maintain tissue homeostasis. Dependence receptors are able to induce either survival or cell death in presence or absence of their ligand, respectively. However, their precise mechanism of action and their physiological importance are still elusive for most of them including the MET receptor. We evidence that pro-apoptotic fragment generated by caspase cleavage of MET localizes to the mitochondria-associated membrane region. This fragment triggers a calcium transfer from endoplasmic reticulum to mitochondria, which is instrumental for the apoptotic action of the *For correspondence: receptor. Knock-in mice bearing a mutation of MET caspase cleavage site highlighted that p40MET [email protected] (AF); production is important for FAS-driven hepatocyte apoptosis, and demonstrate that MET acts as a [email protected] (DT) dependence receptor in vivo. Our data shed light on new signaling mechanisms for dependence †These authors contributed receptors’ control of cell survival/death balance, which may offer new clues for the pathophysiology equally to this work of epithelial structures.
    [Show full text]
  • Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside
    Published OnlineFirst November 19, 2014; DOI: 10.1158/0008-5472.CAN-14-1932 Cancer Review Research Thirty Years of Research on Met Receptor to Move a Biomarker from Bench to Bedside Alessandro Furlan1, Zoulika Kherrouche1,Remi Montagne1, Marie-Christine Copin1,2, and David Tulasne1 Abstract Met receptor tyrosine kinase was discovered in 1984 as an oncogene. Thirty years later, Met and its ligand hepatocyte growth factor/scatter factor are promising targets for the novel therapies developed to fight against cancers, with more than 240 clinical trials currently conducted. In this review, we offer to trace and highlight the most recent findings of the exemplary track record of research on Met receptor, which allowed moving this biomarker from bench to bedside. Indeed, three decades of basic research unravelled the structural basis of the ligand/receptor interaction and their complex downstream signaling network. During this period, animal models highlighted their crucial role in the development and homeostasis of epithelial organs. In parallel, involvement of Met in tumorigenesis was confirmed by the direct association of its deregulation to poor prognosis in numerous cancers. On the basis of these data, pharmaceutical companies developed many Met inhibitors, some of which are in phase III clinical trials. These impressive achievements should not detract from many questions that still remain, such as the precise Met signaling involvement in development or homeostasis of specific epithelial structures. In addition, the processes involving Met in resistance to current therapies or the appearance of resistances to Met-targeted therapies are far from being fully understood. Cancer Res; 74(23); 6737–44.
    [Show full text]
  • Death Pathways Activated in the Neurotrophic Factror-Deprived Neurons
    Death pathways activated in the neurotrophic factor-deprived neurons Li-ying Yu The Finnish Graduate School of Neuroscience Institute of Biotechnology and Department of Biological and Environmental Sciences Faculty of Biosciences University of Helsinki Academic dissertation To be presented for public criticism, with the permission of the Faculty of Biosciences of the University of Helsinki, in the auditorium 2402 at Viikki Biocenter 3 on the 13th of February 2009, at 12 o’clock noon. Helsinki 2009 Supervised by: Docent Urmas Arumäe Institute of Biotechnology University of Helsinki Finland Reviewed by: Docent Matti Airaksinen Neuroscience Center University of Helsinki Finland And Docent Esa Kuismanen Department of Biosciences Division of Biochemistry University of Helsinki Finland Opponent: Professor Dale E. Bredesen Buck Institute for Age Research Novato, California United States of America ISBN 978-952-10-5272-9 (pbk) ISBN 978-952-10-5273-6 (PDF) ISSN 1795-7079 Yliopistopaino, Helsinki, 2009 咃㒠䤓㦏䓀 㪝䚞 㹔 TABLE OF CONTENTS ABBREVIATIONS LIST OF ORIGINAL PUBLICATIONS ABSTRACT 1. REVIEW OF THE LITERATURE ..........................................................................1 1.1. Programed cell death ............................................................................................1 1.1.1. Programed cell death in the development of nervous system.....................1 1.2. Neurotrophic factors .............................................................................................2 1.2.1. Neurotrophin family ...................................................................................3
    [Show full text]
  • The Trkc Receptor Induces Apoptosis When the Dependence Receptor Notion Meets the Neurotrophin Paradigm
    The TrkC receptor induces apoptosis when the dependence receptor notion meets the neurotrophin paradigm Servane Tauszig-Delamasure*, Li-Ying Yu†, Jorge Ruben Cabrera*, Jimena Bouzas-Rodriguez*, Catherine Mermet- Bouvier*, Catherine Guix*, Marie-Claire Bordeaux*, Urmas Aruma¨ e†, and Patrick Mehlen*‡ *Apoptosis, Cancer and Development Laboratory, Equipe Labellise´e La Ligue, Centre National de la Recherche Scientifique, Unite´Mixte de Recherche 5238, Universite´de Lyon, Centre Le´onBe´ rard, 69008 Lyon, France; and †Research Program in Molecular Neurobiology, University of Helsinki, P.O. Box 56, Viikki Biocenter, FIN-00014, Helsinki, Finland Edited by Hans Thoenen, Max Planck Institute of Neurobiology, Martinsried, Germany, and approved June 21, 2007 (received for review February 9, 2007) The TrkC/NT-3 receptor/ligand pair is believed to be part of the neuron migration or localization during the development of the classic neurotrophic theory claiming that neuronal death occurs by nervous system and to inhibit tumor growth in adult. This activity default when neurotrophic factors become limited, through loss of has been exemplified in vivo with the dependence receptor survival signals. Here, we show that TrkC is a dependence receptor Patched and the survival of neuroepithelial cells in the devel- and, as such, induces caspase-dependent apoptotic death in the oping spinal cord (4) as well as for the netrin-1 receptors DCC absence of NT-3 in immortalized cells, a proapoptotic activity and/or UNC5H in colorectal tumorigenesis (5). Here, we pro- inhibited by the presence of NT-3. This proapoptotic activity of TrkC vide evidence that the protein tyrosine kinase receptor TrkC, a relies on the caspase-mediated cleavage of the intracellular domain main cognate receptor for NT-3, is also a dependence receptor.
    [Show full text]
  • Receptors That Mediate Cellular Dependence
    Cell Death and Differentiation (2005) 12, 1031–1043 & 2005 Nature Publishing Group All rights reserved 1350-9047/05 $30.00 www.nature.com/cdd Review Receptors that mediate cellular dependence DE Bredesen*,1,2, P Mehlen1,3 and S Rabizadeh1 cell death (PCD) initiated by a loss of adhesion. Other cells may undergo PCD following the withdrawal of trophic factors 1 The Buck Institute for Age Research, Novato, CA 94945, USA (e.g., the neurotrophins), cytokines, hormonal support, 2 University of California, San Francisco, San Francisco, CA 94143, USA electrical activity, or other stimuli.2 3 Apoptose, Cancer et De´veloppement, Centre Le´on Be´rard – CNRS FRE2870, Depending on the cell type and its state of differentiation, 28 rue Laennec, 69008 Lyon, France cells require different supportive stimuli for survival. For * Corresponding author: DE Bredesen, The Buck Institute for Age Research, 8001 Redwood Blvd., Novato, CA 94945, USA. example, prostate epithelial cells may require testosterone for Tel: þ 1 415 209 2084; Fax: þ 1 415 209 2230; survival, and for such cells the withdrawal of testosterone leads E-mail: [email protected] to apoptosis. Therefore, prostate neoplasms are often treated by withdrawing testosterone because this induces apoptosis, Received 08.3.05; revised 30.3.05; accepted 26.4.05 and thus tumor shrinkage; unfortunately, the few remaining Edited by G Melino cells that are androgen independent typically repopulate the tumors, and therefore alternative therapy is required. Abstract For any given required stimulus, withdrawal leads to PCD; that is, the loss of trophic support somehow triggers an active Cells depend for their survival on stimulation by trophic process of cell suicide.
    [Show full text]
  • Molecular Mechanisms of Cell Death
    Edinburgh Research Explorer Molecular mechanisms of cell death Citation for published version: Galluzzi, L, Vitale, I, Aaronson, SA, Abrams, JM, Adam, D, Agostinis, P, Alnemri, ES, Altucci, L, Amelio, I, Andrews, DW, Annicchiarico-Petruzzelli, M, Antonov, AV, Arama, E, Baehrecke, EH, Barlev, NA, Bazan, NG, Bernassola, F, Bertrand, MJM, Bianchi, K, Blagosklonny, MV, Blomgren, K, Borner, C, Boya, P, Brenner, C, Campanella, M, Candi, E, Carmona-Gutierrez, D, Cecconi, F, Chan, FK-M, Chandel, NS, Cheng, EH, Chipuk, JE, Cidlowski, JA, Ciechanover, A, Cohen, GM, Conrad, M, Cubillos-Ruiz, JR, Czabotar, PE, D'Angiolella, V, Dawson, TM, Dawson, VL, De laurenzi, V, De Maria, R, Debatin, K-M, DeBerardinis, RJ, Deshmukh, M, Di Daniele, N, Di Virgilio, F, Dixit, VM, Dixon, SJ, Duckett, CS, Dynlacht, BD, El-Deiry, WS, Elrod, JW, Fimia, GM, Fulda, S, Garcia-Saez, AJ, Garg, AD, Garrido, C, Gavathiotis, E, Golstein, P, Gottlieb, E, Green, DR, Greene, LA, Gronemeyer, H, Gross, A, Hajnoczky, G, Hardwick, JM, Harris, IS, Hengartner, MO, Hetz, C, Ichijo, H, Jaattela, M, Joseph, B, Jost, PJ, Juin, PP, Kaiser, WJ, Karin, M, Kaufmann, T, Kepp, O, Kimchi, A, Kitsis, RN, Klionsky, DJ, Knight, RA, Kumar, S, Lee, SW, Lemasters, JJ, Levine, B, Linkermann, A, Lipton, SA, Lockshin, RA, Lopez-Otin, C, Lowe, SW, Luedde, T, Lugli, E, MacFarlane, M, Madeo, F, Malewicz, M, Malorni, W, Manic, G, Marine, J-C, Martin, SJ, Martinou, J-C, Medema, JP, Mehlen, P, Meier, P, Melino, S, Miao, EA, Molkentin, JD, Moll, UM, Munoz-Pinedo, C, Nagata, S, Nunez, G, Oberst, A, Oren, M, Overholtzer,
    [Show full text]
  • Opposing Roles of Netrin-1 and the Dependence Receptor DCC in Cancer Cell Invasion, Tumor Growth and Metastasis
    Oncogene (2007) 26, 5615–5625 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc ORIGINAL ARTICLE Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis S Rodrigues1,2, O De Wever1,3, E Bruyneel3, RJ Rooney4 and C Gespach1,2 1INSERM, U673, Paris, France; 2Universite´ Pierre et Marie Curie-Paris 6, Faculte´ de Me´decine, Laboratory of Molecular and Clinical Oncology of Solid Tumors, Paris, France; 3Ghent University Hospital, Laboratory of Experimental Cancerology, Ghent, Belgium and 4Genome Explorations Inc., Memphis, TN, USA Deleted in colon cancer (DCC) and UNC5 function as Introduction netrin dependence receptors by inducing apoptosis in the absence of their ligand and accordingly were recently Netrin-1 belongs to a family of laminin-related secreted designated as putative conditional tumor suppressors. proteins expressed in the brain and peripheral tissues Herein, we determined whether netrin-1 and its receptors (Serafini et al., 1994). Netrins act through immunoglo- are implicated in cancer cell invasion and tumor progres- bulin-like transmembrane receptors, namely deleted sion. Expression of DCC, UNC5 and adenosine in colon cancer (DCC)/neogenin and UNC5A-D, as A2B-receptors (A2B-Rs) was investigated by reverse well as the G-protein-coupled adenosine A2B-receptor transcription polymerase chain reaction in human colon (A2B-R), acting as a DCC co-receptor (Arakawa, 2004). cancer cells. The impact of DCC restitution and netrin-1 Somatic loss of heterozygosity at chromosome 18q, was evaluated on collagen type I invasion, tumor growth frequently observed in colon, pancreatic and breast and metastasis in nude mice, cancer cell survival and gene cancers, is often associated with loss and abnormalities expression profiling.
    [Show full text]
  • Dependence Receptor Trkc Is a Putative Colon Cancer Tumor
    Dependence receptor TrkC is a putative colon cancer SEE COMMENTARY tumor suppressor Anne-Laure Genevoisa,1, Gabriel Ichima,1, Marie-May Coissieuxa, Marie-Pierre Lambertb, Fabrice Laviala, David Goldschneidera, Loraine Jarrosson-Wuillemea, Florian Lepinassec, Géraldine Gouyssec, Zdenko Hercegb, Jean-Yves Scoazecc, Servane Tauszig-Delamasurea,2, and Patrick Mehlena,2,3 aApoptosis, Cancer and Development Laboratory, Equipe labellisée “La Ligue,” LabEx DEVweCAN, Centre de Recherche en Cancérologie de Lyon, Institut National de la Santé et de la Recherche Médicale Unité 1052, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5286, Université de Lyon, Centre Léon Bérard, 69008 Lyon, France; bEpigenetics Group, International Agency for Research on Cancer, 69008 Lyon, France; and cEndocrine Differentiation Laboratory, Centre de Recherche en Cancérologie de Lyon, Institut National de la Santé et de la Recherche Médicale Unité 1052, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5286, Université de Lyon, Hospices Civils de Lyon, Hôpital Edouard Herriot, Anatomie Pathologique, 69437 Lyon, France † Edited by Albert de la Chapelle, Ohio State University Comprehensive Cancer Center, Columbus, OH, and approved December 7, 2012 (received for review July 19, 2012) The TrkC neurotrophin receptor belongs to the functional depen- bound by their respective trophic ligands. These receptors thus dence receptor family, members of which share the ability to induce create cellular states of dependence on their respective
    [Show full text]
  • ATG9A Protects the Plasma Membrane from Programmed and Incidental Permeabilization
    ARTICLES https://doi.org/10.1038/s41556-021-00706-w ATG9A protects the plasma membrane from programmed and incidental permeabilization Aurore Claude-Taupin 1,2, Jingyue Jia1,2, Zambarlal Bhujabal3, Meriem Garfa-Traoré4, Suresh Kumar1,2, Gustavo Peixoto Duarte da Silva 1,2,5, Ruheena Javed1,2, Yuexi Gu1,2, Lee Allers1,2, Ryan Peters1,2, Fulong Wang1,2, Luciana Jesus da Costa5, Sandeep Pallikkuth6, Keith A. Lidke 6, Mario Mauthe7, Pauline Verlhac7, Yasuo Uchiyama8, Michelle Salemi9, Brett Phinney 9, Sharon A. Tooze 10, Muriel C. Mari7, Terje Johansen 3, Fulvio Reggiori 7 and Vojo Deretic 1,2 ✉ The integral membrane protein ATG9A plays a key role in autophagy. It displays a broad intracellular distribution and is present in numerous compartments, including the plasma membrane (PM). The reasons for the distribution of ATG9A to the PM and its role at the PM are not understood. Here, we show that ATG9A organizes, in concert with IQGAP1, components of the ESCRT system and uncover cooperation between ATG9A, IQGAP1 and ESCRTs in protection from PM damage. ESCRTs and ATG9A phenocopied each other in protection against PM injury. ATG9A knockouts sensitized the PM to permeabilization by a broad spectrum of microbial and endogenous agents, including gasdermin, MLKL and the MLKL-like action of coronavirus ORF3a. Thus, ATG9A engages IQGAP1 and the ESCRT system to maintain PM integrity. he autophagy1,2 and ESCRT systems3–5 both act in the remodel- is present in numerous intracellular compartments, including the ling of cellular membranes and contribute to a range of intra- trans-Golgi network and early and recycling endosomes21,22, and traf- cellular homeostatic functions and biological processes.
    [Show full text]